Texas Life Science Forum: Mongoose Bio is advancing a novel TCR-T program that was developed at MD Anderson and plans to take it into the clinic next year

blonca9
Nov 7, 2024
1 min read

CEO Neil Warma describes the unique approach to TCRs that could reduce toxicity and increase persistence compared to other programs. Plus, his view from beings a veteran to the Houston biotech scene.

Brought to you by

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Texas Life Science Forum: Mongoose Bio is advancing a novel TCR-T program that was developed at MD Anderson and plans to take it into the clinic next year

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight